Want to see NXGL full AI Analyst Report?
NXGL Stock Chart & Stats
$0.44
>-$0.01(-0.57%)
At close: 4:00 PM EDT
$0.44
>-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$0.40 - $2.89
Previous Close$0.44
Volume5.00
Average Volume (3M)50.95K
Market Cap
$4.90M
Enterprise Value$7.85
Total Cash (Recent Filing)$208.00K
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding9,225,242
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.84
Price to Sales (P/S)1.11
P/FCF Ratio-9.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$24.06M
Bulls Say, Bears Say
Bulls Say
Transformative Acquisition (pro Forma Revenue ~3x)The BioNX acquisition materially scales NexGel’s revenue base and is projected to be immediately accretive to profitability. A threefold revenue step-up supports fixed-cost absorption, improves operating leverage, and creates capacity to fund commercialization and R&D over the next 2–6 months and beyond.
Commercial Footprint: BioNX In ~500 U.S. HospitalsHaving commercial products placed in ~500 hospitals gives NexGel durable market access and recurring institutional demand. Hospital adoption creates long sales cycles but higher retention, credibility for new device launches, and a platform for cross-selling regenerative and hydrogel offerings.
Improved Gross Margin (~39% TTM)A sustained ~39% gross margin signals stronger product economics and manufacturing efficiency in hydrogel production. Higher gross margins provide room to absorb SG&A and integration costs, enhancing the company’s path to positive operating leverage as revenue scales post-acquisition.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing negative OCF and FCF (~-$1.4M TTM) limit NexGel’s ability to self-fund growth or cushion integration risks. Reliance on external financing increases dilution and constrains capital allocation for sales, manufacturing capacity, and R&D, posing a durable headwind until cash flow turns positive.
Rising Leverage (debt-to-equity ~1.05)Debt roughly equal to equity erodes balance-sheet flexibility for a small company. Higher leverage increases fixed obligations, limits borrowing capacity, and magnifies risk if post-acquisition synergies or revenue ramps underperform, making funding needs a persistent strategic constraint.
Near-term SG&A Step-up And Constrained LiquidityAn incremental ~$500K/month cost run-rate plus only ~$1.8M cash on hand tightens NexGel’s runway. Elevated recurring SG&A to commercialize BioNX increases execution risk and raises the probability of additional financings, which could dilute shareholders and strain integration over a multimonth horizon.
NexGel Inc News
NXGL FAQ
What was NexGel Inc’s price range in the past 12 months?
NexGel Inc lowest stock price was $0.40 and its highest was $2.89 in the past 12 months.
What is NexGel Inc’s market cap?
NexGel Inc’s market cap is $4.90M.
When is NexGel Inc’s upcoming earnings report date?
NexGel Inc’s upcoming earnings report date is Aug 18, 2026 which is in 12 days.
How were NexGel Inc’s earnings last quarter?
Currently, no data Available
Is NexGel Inc overvalued?
According to Wall Street analysts NexGel Inc’s price is currently Undervalued.
Does NexGel Inc pay dividends?
NexGel Inc does not currently pay dividends.
What is NexGel Inc’s EPS estimate?
NexGel Inc’s EPS estimate is -0.12.
How many shares outstanding does NexGel Inc have?
NexGel Inc has 9,225,242 shares outstanding.
What happened to NexGel Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NexGel Inc?
Currently, no hedge funds are holding shares in NXGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NexGel Inc
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
NXGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a transformational acquisition (BioNX), strategic financing and partnership with Sequence LifeScience, strengthened leadership, a commercial product portfolio in ~500 hospitals, and pro forma projections to triple revenue to ~$35M and be accretive — all significant positives. Offsetting these are near‑term operational and liquidity pressures: Q1 revenue declined ~5.7% YoY, cash on hand fell to $1.8M, SG&A is elevated, and some legacy consumer products and key customer relationships have underperformed. Management reported early signs of recovery and initial BioNX sales beginning in Q2, but timing and execution risk remain notable.View all NXGL earnings summariesNXGL Stock 12 Month Forecast
Average Price Target
$2.00
▲(354.55% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
Sanara MedTech
―
Femasys
―
Ownership Overview
4.73% Insiders
1.13% Mutual Funds
0.12% Other Institutional Investors
93.49% Public Companies and
Individual Investors